VistaGen Therapeutics
VTGN
12 hedge funds and large institutions have $2.68M invested in VistaGen Therapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.14% less ownership
Funds ownership: 0.67% → 0.53% (-0.14%)
57% less capital invested
Capital invested by funds: $6.27M → $2.68M (-$3.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$95.9K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$29.5K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$10.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.05K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$243 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$1.32M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$20.5K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.78K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $1.07M | – | – | – |
|
|
2
Parallax Volatility Advisers
San Francisco,
California
| $541K | -$20.5K | -253 | -3% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $340K | -$7.78K | -96 | -2% |
|
|
NC
4
Nexthera Capital
New York
| $271K | – | – | – |
|
|
DADC
5
D.A. Davidson & Co
Great Falls,
Montana
| $178K | +$10.8K | +133 | +5% |
|
|
LTFS
6
Ladenburg Thalmann Financial Services
Miami,
Florida
| $88K | +$95.9K | +1,184 | +371% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $77K | +$4.05K | +50 | +4% |
|
8
Geode Capital Management
Boston,
Massachusetts
| $58K | – | – | – |
|
9
HighTower Advisors
Chicago,
Illinois
| $39K | – | – | – |
|
|
10
Northern Trust
Chicago,
Illinois
| $21K | +$29.5K | +364 | New |
|
|
HFM
11
Hartford Financial Management
Hartford,
Connecticut
| $2K | – | – | – |
|
|
NLVP
12
New Leaf Venture Partners
New York
| – | -$1.32M | -11,765 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$4K | -35 | Closed |
|
|
AIM
14
Acrospire Investment Management
Chicago,
Illinois
| – | +$243 | +3 | New |
|
VTGN Hedge Fund Activity: Q1 2017 in Review
12 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2017, worth a combined $2.68M — down 57% from $6.27M a quarter earlier.
Fund positioning in VTGN was balanced in Q1 2017: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $95.9K. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $1.32M sold.
- 12 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $2.68M of VistaGen Therapeutics stock for Q1 2017, down 57% quarter-over-quarter.
- 2 funds opened new VistaGen Therapeutics positions in Q1 2017 and 2 closed out, a net change of 0 holders.
- The largest VistaGen Therapeutics buyer in Q1 2017 was Ladenburg Thalmann Financial Services, an estimated $95.9K added.
- The largest VistaGen Therapeutics seller in Q1 2017 was New Leaf Venture Partners, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2017.